B
Bull
Bull · 25%MEIP
$8.39
情境價格
$3.070
+0.320 (+10.43%)收盤時
Loading chart…
- High
- 3.250
- Open
- 2.890
- VWAP
- 3.06
- Vol
- 4.03M
- Mkt Cap
- 19.66M
- Low
- 2.850
- Amount
- 12.33M
- EV/EBITDA, TTM
- 0.00
Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
Analyst Ratings (3)
Hold
1 Buy
2 Hold
0 Sell
Current: 3.07
最低
—
平均
—
最高
—
Laidlaw & Co.
Hold
—
2024-07-23
Laidlaw & Co.
2024-07-23
目標價
—
Hold
Stifel
Hold
$7
2024-04-12
Stifel
2024-04-12
目標價
$7
Hold
Stifel
Hold
$7
2024-02-14
Stifel
2024-02-14
目標價
$7
Hold
Stifel
Hold
$9
2023-09-27
Stifel
2023-09-27
目標價
$9
Hold
Brookline Capital
Strong Buy
$80
2023-05-23
Brookline Capital
2023-05-23
目標價
$80
Strong Buy
估值指標
The current forward P/E ratio for MEI Pharma Inc (MEIP) is -0.83, compared to its 5-year average forward P/E of -1.09.
Alphio AI Price Scenarios for MEIP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
4.509-10NewsfilterMEI Pharma, Inc. Changes Name to Lite Strategy, Inc. and Introduces New NASDAQ Ticker 'LITS'
4.509-08BenzingaRobinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
4.508-05BenzingaMEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset
4.507-21BenzingaUS Stocks Likely To Open Higher Despite Trump Administration's 'Hard Deadline' Warning For Tariffs — Verizon, Domino's Pizza Earnings In Focus
8.507-18BenzingaWhy Is MEI Pharma Stock Soaring On Friday?
MEIP FAQ — answered by Alphio AI
Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover MEIP: 1 rate it Buy, 2 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。